Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

Hans Hammers, MD, PhD
Published: Friday, May 05, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma (RCC).

It is time to revisit vaccines, Hammers says, particularly in combinations. Approaches to this include allogenic vaccines for easy, over-the-counter use, and tailor-made vaccines to fit the needs of a specific patient.
 


Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma (RCC).

It is time to revisit vaccines, Hammers says, particularly in combinations. Approaches to this include allogenic vaccines for easy, over-the-counter use, and tailor-made vaccines to fit the needs of a specific patient.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x